Feng, Xiaodong_ Xie, Hong-Guang - Applying pharmacogenomics in therapeutics-CRC Press (2016)

30 Applying Pharmacogenomics in Therapeutics
119. Ciszkowski, C., et al. Codeine, ultrarapid-metabolism genotype, and postoperative
death. N Engl J Med, 2009; 361(8): 827–8.
120. Dalen, P., et al. Quick onset of severe abdominal pain after codeine in an ultrarapid
metabolizer of debrisoquine. Ther Drug Monit, 1997; 19(5): 543–4.
121. Lotsch, J., et al. Genetic predictors of the clinical response to opioid analgesics: Clinical
utility and future perspectives. Clin Pharmacokinet, 2004; 43(14): 983–1013.
122. Koren, G., et al. Pharmacogenetics of morphine poisoning in a breastfed neonate of
a codeine-prescribed mother. Lancet, 2006; 368(9536): 704.
123. Kurtz, M., P. Black Golde, and N. Berlinger. Ethical considerations in CYP2D6 genotype
testing for codeine-prescribed breastfeeding mothers. Clin Pharmacol Ther, 2010;
88(6): 760–2.
124. Codeine. Breast feeding. Clinical pharmacology. 2011. Available from: http://www.​
clinicalpharmacology-ip.com/Forms/Monograph/monograph.aspx?cpnum=146&sec=​
monpreg (accessed August 30, 2011).
125. Ferner, R.E. Did the drug cause death? Codeine and breastfeeding. Lancet, 2008;
372(9639): 606–8.
126. Gasche, Y., et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism.
N Engl J Med, 2004; 351(27): 2827–31.
127. Madadi, P. and G. Koren. Pharmacogenetic insights into codeine analgesia: Implications
to pediatric codeine use. Pharmacogenomics, 2008; 9(9): 1267–84.
128. FDA. FDA Public Health Advisory. Use of Codeine by Some Breastfeeding Mothers May
Lead to Life-Threatening Side Effects in Nursing Babies. 2007. Available from: http://www.
fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/
ucm054717.htm (accessed September 8, 2015).
129. de Leon, J. AmpliChip CYP450 test: Personalized medicine has arrived in psychiatry.
Expert Rev Mol Diagn, 2006; 6(3): 277–86.
130. Roche. AmpliChip CYP450 Test. Available from: http://molecular.roche.com/ASSAYS/
Pages/AmpliChipCYP450Test.aspx (accessed August 30, 2011).
131. Coumadin Tablets. Warfarin Sodium Tablets. Prescribing Information. Bristol-Myers
Squibb Company, Princeton, NJ, 2010.
132. Wysowski, D.K., P. Nourjah, and L. Swartz. Bleeding complications with warfarin
use: A prevalent adverse effect resulting in regulatory action. Arch Intern Med, 2007;
167(13): 1414–19.
133. Higashi, M.K., et al. Association between CYP2C9 genetic variants and
anticoagulation-related outcomes during warfarin therapy. JAMA, 2002; 287:
1690–8.
134. Demirkan, K., et al. Response to warfarin and other oral anticoagulants: Effects of
disease states. S Med J, 2000; 93(5): 448–54; quiz 455.
135. Garcia, D., et al. Warfarin maintenance dosing patterns in clinical practice: Implications
for safer anticoagulation in the elderly population. Chest, 2005; 127(6): 2049–56.
136. Holbrook, A.M., et al. Systematic overview of warfarin and its drug and food interactions.
Arch Intern Med, 2005; 165(10): 1095–106.
137. Kurnik, D., et al. Complex drug-drug-disease interactions between amiodarone, warfarin,
and the thyroid gland. Medicine (Baltimore), 2004; 83(2): 107–13.
138. Takeuchi, F., et al. A genome-wide association study confirms VKORC1, CYP2C9, and
CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet, 2009; 5(3):
e1000433.
139. Lee, C.R., J.A. Goldstein, and J.A. Pieper. Cytochrome P450 2C9 polymorphisms:
A comprehensive review of the in-vitro and human data. Pharmacogenetics, 2002;
12(3): 251–63.
140. Schwarz, U.I. Clinical relevance of genetic polymorphisms in the human CYP2C9
gene. Eur J Clin Invest, 2003; 33(Suppl 2): 23–30.